Person:
Fernández Ruiz, Virginia Esperanza

Profile Picture
Name
Fernández Ruiz, Virginia Esperanza
publication.page.department
Universidad de Murcia. Departamento de Enfermería
Repository logoRepository logo

Filters

2024 - 20252
2
2
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Corporal composition and gut microbiome modification through exclusion dietary intervention in adult patients with Crohn’s disease: protocol for a prospective, interventional, controlled, randomized clinical trial
    (MDPI, 2025-06-05) Cano-Mármol, Rosario Paloma; Fernández Ruiz, Virginia Esperanza; Martínez-Pascual, Cristina; Ros-Madrid, Inmaculada; Martín-Pozuelo del Pozo, Gala; Oliva-Bolarín, Alba; Martínez-Sánchez, María Antonia; Egea Valenzuela, Juan; Núñez-Sánchez, María Ángeles; Ramos-Molina, Bruno; Ruiz Alcaraz, Antonio José; Ferrer Gómez, Mercedes; Bioquímica y Biología Molecular B e Inmunología; Facultad de Biología
    Background: Crohn’s disease (CD) is an inflammatory bowel disease in which there is an alteration in the homeostasis and functionality of the intestinal mucosa accompanied by a dysbiosis of the commensal microbiota. The analysis of different dietary strategies to achieve CD remission and reduce gastrointestinal symptoms concludes that it is necessary to restrict the intake of ultra-processed products and to promote the consumption of those with anti-inflammatory effects that improve intestinal permeability and dysbiosis. Methods: Based on previous studies conducted in other cohorts, mainly pediatric, we propose an experimental, prospective, randomized study in patients with active CD who do not show improvement with conventional pharmacological treatment. The control group will receive standard nutritional recommendations while the intervention group will be prescribed an exclusion diet supplemented with enteral nutrition. Results: Patients in the intervention group are expected to exhibit increased lean body mass and reduced visceral fat, as measured by bioelectrical impedance analysis (BIA), alongside higher rates of clinical remission (CDAI), decreased inflammatory markers, and improved gut microbiota composition. Additionally, improvements in health-related quality of life are anticipated, as assessed by validated questionnaires. Conclusions: In the present project, we plan to conduct a detailed study to determine the potential of the exclusion diet for the treatment and remission of CD in adult patients, with the hypothesis that this nutritional intervention will be able to modify and improve intestinal dysbiosis, inflammatory status, and clinical and body composition markers in these patients.
  • Thumbnail Image
    Publication
    Restricted
    Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity
    (Oxford University Press, 2024-01-13) Núñez-Sánchez, María Ángeles; Martínez-Sánchez, María Antonia; Martínez-Montoro, José Ignacio; Balaguer-Román, Andrés; Murcia-García, Elena; Fernández Ruiz, Virginia Esperanza; Ferrer Gómez, Mercedes; Martínez Cáceres, Carlos Manuel; Sledzinski, Tomasz; Frutos Bernal, María Dolores; Hernández-Morante, Juan José; Fernández-García, José Carlos; Queipo-Ortuño, María Isabel; Ruiz Alcaraz, Antonio José; Mika, Adriana; Ramos-Molina, Bruno; Bioquímica y Biología Molecular B e Inmunología; Facultad de Biología
    Context. Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development. Objective. To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors. Methods. This was a case–control study in patients with obesity undergoing bariatric surgery at a university hospital between January 2020 and December 2021. Participants were distributed in 3 groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction–associated steatohepatitis (n = 32). Hepatic and serum FA levels were determined by gas chromatography-mass spectrometry. Nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by reverse transcription quantitative polymerase chain reaction. Results. The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared with those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD, being significantly different between the 3 groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD. Conclusion. Alterations in hepatic FA levels in MASLD patients were due to enhancement of de novo lipogenesis in the liver.
Ir a Estadísticas